Rational Rollout of New Medicines for Diseases of Poverty
Tuberculosis and malaria kill more than two million people each year, primarily in low- and middle-income countries. Many of these deaths could be prevented if companies had incentives to produce medications for diseases of poverty more quickly and make them available more cheaply. Once effective new medicines for diseases of poverty are produced, government policies largely determine how or whether they are provided to the people most in need. Governments with high disease burdens must optimize their policies to ensure safe and timely access to new medicines. The world health community must get behind action to combat infectious disease drug resistance. Increasing pharmacovigilance (especially, removing inferior medicines from the supply chain) and establishing fully funded sustainable treatment plans will help achieve this aim.